Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Australia / NCT06901167
Recruiting Not applicable

Evaluation of a Residential In-Reach Program in Regional and Rural Australia

NCT06901167 · tracked via the Priya Life Science Australia tracker
Sponsor
Monash University
Phase
Not applicable
Started
2025-05-01
Last updated
2025-05-30

Condition(s) studied

AgedAcute Disease

Investigational drug(s) / intervention(s)

Residential In-Reach Program

Residential In-Reach Program: All enrolled residential aged care homes will be able to access the residential-in-reach (RIR) program intervention. The RIR program provides a consultation service from a central hospital to an aged care facility in the Grampians region in the state of Victoria, Australia. Aged care staff will make a telehealth referral to central hub, where a nurse practitioner will triage the patient and make recommendations (for example, monitor resident condition, more examples: comprehensive assessment for unwell residents, liaison with the General Practitioners for diagnosis and treatment plan, provide education and support to staff) or further referrals (for example, refer to geriatrician or call an ambulance).

Study summary

Residential In-Reach (RIR) programs are designed to provide responsive care for residents in residential aged care homes (RACH) with the aim of avoiding unnecessary hospital transfers. The evidence for their clinical and cost-effectiveness and implementation has been established in urban settings, but there is a small amount of low-quality evidence for rural and regional settings. The Grampians Region Health Service Partnership Resi-In-Reach Redesign Committee will be implementing a new RIR program to be offered to all RACHs in the Grampians region, this project aims to evaluate the clinical and cost-effectiveness of this program, and its implementation in the rural and regional setting. A stepped-wedge trial will be conducted so that as the RIR program is gradually rolled-out across the region, outcomes can be compared in the same facilities across time and between different facilities. The primary outcome measure will be presentation to emergency departments and urgent care centres, and data will also be collected on other clinical outcomes and barriers and enablers of implementing the program. It is anticipated that there will be a reduction in hospital presentations, and a range of barriers and enablers unique to the rural and regional setting will emerge.

Eligibility

Sex
ALL
Min age
65 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Health services that have emergency departments and/or emergency care centres that admit residents from residential aged care homes (RACH) * RACHs that do not currently have access to RIR programs * health service staff who have been involved with the set-up and delivery of the RIR program, * RACH staff who have experience of or accessing the RIR service for residents at least once, * residents living at a RACH who has experienced receiving medical care from the RIR program and can provide informed consent, or a family member of the resident, * general practitioners whose case load includes residents from RACHs. Exclusion Criteria: • RACHs that already have access to a RIR program will be excluded

Primary outcome measure(s)

  • Rate of presentations from residential aged care homes to emergency departments and emergency care centres — From enrolment to the end of the trial for 14 months
    Primary clinical effectiveness outcome Collection schedule: * Once at the end of the evaluation * At the level of each residential aged care home presentation to hospital each month Collection approach: Extraction from hospital records and extraction from residential aged care home systems

Trial sites (8)

FacilityCityRegionStatus
East Grampians Health Service Ararat Victoria Recruiting
Grampians Health Ballarat Victoria Recruiting
Beaufort and Skipton Health Service Beaufort Victoria Recruiting
Central Highlands Rural Health Daylesford Victoria Recruiting
Maryborough District Health Service Maryborough Victoria Recruiting
West Wimmera Health Service Nhill Victoria Recruiting
East Wimmera Health Service Saint Arnaud Victoria Recruiting
Rural Northwest Health Warracknabeal Victoria Recruiting

More Monash University trials in Australia

Study Investigating the Role of Routine Screening and Molecular Characterisation of Brain Metastasis in the Management of High-risk Metastatic Breast Cancer Starting soon
A Natural History Study to TRACK Brain and Spinal Cord Changes in Individuals with Friedreich Ataxia (TRACK-FA) Active, not recruiting
Healthcare and Community Service Utilisation in Older Survivors of Critical Illness Starting soon
Statins in Reducing Events in the Elderly (STAREE) Heart Sub-study Active, not recruiting
Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy: Starting Immunoglobulin (Start Ig) Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06901167 on ClinicalTrials.gov ↗ ← All trials in Australia